"The check has already been cut."
The check has not been cut. The truth is that the Merck deal with the US is subject to an approval or EUA, neither of which have been issued.
In fact Merck applied for an EUA based on interim data that has since been updated to show a notably lower rate of effectiveness.
A panel of "outside experts" has been tasked "to discuss whether the benefits of the drug outweigh the risks and whether the population for whom the drug should be authorized should be limited."
So THAT is the truth. These things are not:
"The purpose has been served. The taxpayers have been milked."
Eventually, maybe inevitably, your assertions will become the truth. But the ongoing context that is being created of "everything but B sucks" doesn't benefit IPIX the Company or IPIX shareholders at all...it has no value to them. Sour grapes commentary never does, especially when it's not entirely accurate.
People would be wise to consider that they might be providing readers a reminder of their own glass house when they report the less than perfect performances of the "competition". After all, in the Company's own words:
"Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the study’s primary endpoint based on clinical status."
"The number of patients who died totaled eight, four each between active and placebo."
News 
Market Data 
Discover 
AI
